References
- Ujhazy P, Carbone D. Summary of presentations from the 11th targeted therapies for lung cancer meeting: immunotherapy and vaccines for treatment of lung cancer. J Thorac Oncol 2011; 6:Suppl 4 S1815 - 7; http://dx.doi.org/10.1097/01.JTO.0000407570.29900.a5; PMID: 22005542
- Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003; 5:690 - 9; http://dx.doi.org/10.1002/jgm.397; PMID: 12898638
- Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009; 27:379 - 86; http://dx.doi.org/10.1007/s10637-008-9187-3; PMID: 18931824
- Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011; 60:261 - 71; http://dx.doi.org/10.1007/s00262-010-0935-9; PMID: 21069322
- Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008; 3:735 - 44; http://dx.doi.org/10.1097/JTO.0b013e31817c6b4f; PMID: 18594319
- Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12:1125 - 33; http://dx.doi.org/10.1016/S1470-2045(11)70259-5; PMID: 22019520
- Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
- Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503 - 10; http://dx.doi.org/10.1038/ni1582; PMID: 18425107